Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,435 total articles

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Black Diamond Therapeutics, a clinical-stage oncology company, will host a webcast on May 21, 2026, to present updated results from its ongoing Phase 2 trial of Silevertinib in frontline patients with EGFR-mutated non-small cell lung cancer. The company focuses on developing MasterKey therapies that target oncogenic mutations, aiming to overcome re…

Challenger Learning Center of Northeast Alabama Opens Immersive STEM Experience Featuring NASA-Style Mission Simulations

Challenger Learning Center of Northeast Alabama Opens Immersive STEM Experience Featuring NASA-Style Mission Simulations

zSpace, Inc., a technology provider specializing in augmented and virtual reality solutions, announced a partnership with the Challenger Learning Center of Northeast Alabama and the JAX State STEAM Institute to open a new immersive STEM center. The facility offers middle school students NASA-style mission simulations using zSpace's AR/VR technologi…

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

BioCardia, Inc., a Nasdaq-listed company specializing in cellular therapeutics for cardiovascular and pulmonary diseases, announced its upcoming participation in a virtual fireside chat during the Alliance Global Partners Healthcare Company Showcase. The event, scheduled for May 20, 2026, will provide insights into BioCardia's therapeutic platforms…

Inspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX" on May 20, 2026, Following Strategic Focus on AME and Quantum Connectivity

Inspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX" on May 20, 2026, Following Strategic Focus on AME and Quantum Connectivity

Inspira Technologies announced a corporate name change to QTREX Quantum Ltd. and will begin trading under the new Nasdaq ticker symbol QTEX on May 20, 2026. This rebranding reflects the company’s strategic focus on its Additively Manufactured Electronics (AME) platform to develop advanced manufacturing, high-performance electronics, and quantum con…

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology, Inc. (NASDAQ: CGON), a late-stage biopharmaceutical company, has announced the recipients of the second annual NMIBC Research Fellowship Award in collaboration with the SUO Clinical Trials Consortium. The fellowship supports promising clinical researchers focused on improving treatment outcomes for Non-Muscle Invasive Bladder Cancer (N…

Oxford Lane Capital Corp. Announces April Net Asset Value and Selected Financial Results for the Fourth Fiscal Quarter, and Declaration of Common Stock Distributions for the Months Ending July, August, and September 2026

Oxford Lane Capital Corp. Announces April Net Asset Value and Selected Financial Results for the Fourth Fiscal Quarter, and Declaration of Common Stock Distributions for the Months Ending July, August, and September 2026

Oxford Lane Capital Corp. announced its unaudited estimated net asset value (NAV) as of April 30, 2026, ranging between $11.12 and $11.42 per share, down from $15.51 at December 31, 2025. The company reported net investment income of approximately $54.5 million for Q4 ended March 31, 2026, and declared common stock dividends of $0.20 per share for …

Sunrun Earns Four 2026 Buyer’s Choice Awards from ConsumerAffairs, Including Best Customer Service

Sunrun Earns Four 2026 Buyer’s Choice Awards from ConsumerAffairs, Including Best Customer Service

Sunrun Inc., the leading U.S. provider of home solar and battery storage solutions, has been honored with four 2026 Buyer’s Choice Awards by ConsumerAffairs. The awards recognize Sunrun's excellence in customer service, installation, equipment quality, and value based on verified customer reviews, underscoring the company’s commitment to superior c…

Quantum Cyber Files Non-Provisional Patent Application With the USPTO for EMP-Shielding 3D-Printable Composite Filament for Drone and Defense Electronics

Quantum Cyber Files Non-Provisional Patent Application With the USPTO for EMP-Shielding 3D-Printable Composite Filament for Drone and Defense Electronics

Quantum Cyber N.V. announced the filing of a non-provisional patent application with the USPTO for an innovative electromagnetic pulse (EMP) shielding composite filament designed for 3D printing drone enclosures and defense electronics. This technology offers a lightweight, manufacturable solution to EMP hardening, a critical vulnerability in auton…

Landstar Statement on U.S. Supreme Court Decision

Landstar Statement on U.S. Supreme Court Decision

Landstar System, Inc. addressed the recent U.S. Supreme Court decision in Montgomery v. Caribe Transport II, LLC, which clarifies federal preemption regarding negligent carrier selection claims in freight brokerage. Landstar highlighted its rigorous, technology-enabled carrier qualification processes that align with federal safety standards and exp…

Creative Realities to Participate in Upcoming Craig-Hallum Conference

Creative Realities to Participate in Upcoming Craig-Hallum Conference

Creative Realities, Inc., a Nasdaq-listed provider of digital signage, media, and AdTech solutions, announced its participation in the upcoming Craig-Hallum Institutional Investor Conference. The company offers digital signage platforms and recurring SaaS services across multiple verticals including retail, automotive, and digital-out-of-home adver…

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

Plus Therapeutics announced a strategic partnership with Ephemeral Technologies to deploy a novel AI execution platform that integrates and analyzes proprietary therapeutic, diagnostic, and bioinformatics datasets in central nervous system (CNS) oncology. This collaboration aims to enhance precision neuro-oncology by improving operational efficienc…

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

Alterity Therapeutics announced compelling data presentations supporting progression of their lead compound ATH434 into Phase 3 clinical trials for Multiple System Atrophy (MSA). The Phase 2 trial demonstrated statistically significant slowing of disease progression and favorable biomarker engagement, with novel MRI imaging techniques enabling earl…

Boeing and Gilat Achieve Key In-Cabin Offerability Milestone for Sidewinder Line-fit Multi‑Orbit Solution

Boeing and Gilat Achieve Key In-Cabin Offerability Milestone for Sidewinder Line-fit Multi‑Orbit Solution

Gilat Satellite Networks and Boeing have achieved a milestone to offer Gilat's multi-orbit Sidewinder electronically steered antenna as a future line-fit option for in-flight connectivity (IFC) service providers. This compact ESA will simplify installation, reduce maintenance costs, and enable earlier service entry, supporting advanced broadband co…

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

Zenas BioPharma announced that safety and efficacy results from the Phase 3 INDIGO trial evaluating its lead candidate Obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) will be presented at the EULAR 2026 Congress. The INDIGO trial met its primary and all four key secondary endpoints with high statistical significance, demonstrating a 56% …

Antalpha Reports First Quarter 2026 Results

Antalpha Reports First Quarter 2026 Results

Antalpha Platform Holding Company announced robust Q1 2026 results with 52% year-over-year revenue growth and enhanced profitability driven by its scalable digital asset platform. The acquisition of Aurelion contributed significantly, boosting adjusted EBITDA margin to 64%. The company is advancing its tokenized gold strategy to generate yield and …

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Cullinan Therapeutics announced that the FDA has granted Orphan Drug Designation to CLN-049, a novel FLT3xCD3 T cell engager under investigation for treating relapsed/refractory acute myeloid leukemia (AML). The designation supports the drug's potential to address significant unmet medical needs in AML, including in patients with poor prognosis due…